Esbriet
Product Images NDC 64116-121
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esbriet (NDC 64116-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Intermune, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Esbriet Figure 2)
Figure 1 (Esbriet Figure 3)
The text provides a table showing the mean change in Forced Vital Capacity (FVC) in milliliters (mL) between patients treated with ESBRET and placebo. The dataset includes a total of 278 patients treated with ESBRET and 217 treated with placebo. The table shows the mean change (in mL) in FVC at different time points from baseline up to week 52. However, without further context, it is difficult to draw meaningful conclusions from this data.*
Figure 1 (Esbriet Figure 4)
This is a graph showing the percentage of patients who are alive based on treatment with ESBRIET and Placebo. The HR (Hazard Ratio) for ESBRIET is 0.75 with a 95% confidence interval of 0.51-1.11. The graph plots survival over time in weeks (0-120 weeks) and the number of patients at risk for ESBRIET and Placebo treatment groups.*
Capsules Carton (Esbriet Figure 5)
Each capsule of a medication called "Esbriet" contains 267 mg of the active ingredient pirfenidone. The medication comes in a package with a total of 270 capsules and must be stored at room temperature between 15-30°C. It should be kept out of reach of children. The medication is only available with a prescription.*
Capsules Label (Esbriet Figure 6)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.